Gatehouse Bio, Inc.

WALTHAM, MA · Founded 2017 · CIK 0001840498 · Biotech · Private

AI platform for designing precision oligonucleotide therapeutics guided by small RNA biomarkers

gatehousebio.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$5.4M
1 Form D · Jan 2021
69 months since last filing
Contracts
—
No federal contracts on record
Patents
10
0 granted · 10 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$5,445,379
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2304Acurx Pharmaceuticals, Inc.—$17M
2305Congruence Therapeutics——
2306BICYCLE THERAPEUTICS PLC—$555M
2307Gatehouse Bio, Inc.—$5.4M
2308Synlico Inc.—$5.2M
2309Humonix Biosciences Inc——
2310Deep Origin Inc.—$29M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 2 related persons
  • Neal FosterDirector · Executive Officer
  • David Salzman, Ph.D.Director · Executive Officer

Patents

USPTO · 0 granted of 10
  • Small Rna-based Prognostic Signatures And Therapeutic Compositions For Idiopathic Pulmonary Fibrosisapplication
  • Small Rna Predictors For Alzheimer's Diseaseapplication
  • Small Rna Predictors For Huntington's Diseaseapplication
  • Methods For Identifying And Using Small Rna Predictorsapplication
  • Small Rna-based Prognostic Signatures And Therapeutic Compositions For Idiopathic Pulmonary Fibrosisapplication
  • Small Rna-based Prognostic Signatures And Therapeutic Compositions For Coronary Microvascular Dysfunctionapplication
  • Small Rna-based Prognostic Signatures And Therapeutic Compositions For Idiopathic Pulmonary Fibrosisapplication
  • Small Rna-based Prognostic Signatures And Therapeutic Compositions For Idiopathic Pulmonary Fibrosisapplication
  • Small Rna-based Prognostic Signatures And Therapeutic Compositions For Heart Failureapplication
  • Small Rna-based Prognostic Signatures And Therapeutic Compositions For Coronary Microvascular Dysfunctionapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.